Cargando…

The collateral activity of RfxCas13d can induce lethality in a RfxCas13d knock-in mouse model

BACKGROUND: The CRISPR-Cas13 system is an RNA-guided RNA-targeting system and has been widely used in transcriptome engineering with potentially important clinical applications. However, it is still controversial whether Cas13 exhibits collateral activity in mammalian cells. RESULTS: Here, we find t...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yunfei, Xu, Junjie, Guo, Xuefei, Li, Zhiwei, Cao, Lili, Liu, Shengde, Guo, Ying, Wang, Guodong, Luo, Yujie, Zhang, Zeming, Wei, Xuemei, Zhao, Yingchi, Liu, Tongtong, Wang, Xiao, Xia, Huawei, Kuang, Ming, Guo, Qirui, Li, Junhong, Chen, Luoying, Wang, Yibing, Li, Qi, Wang, Fengchao, Liu, Qinghua, You, Fuping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893547/
https://www.ncbi.nlm.nih.gov/pubmed/36726140
http://dx.doi.org/10.1186/s13059-023-02860-w
Descripción
Sumario:BACKGROUND: The CRISPR-Cas13 system is an RNA-guided RNA-targeting system and has been widely used in transcriptome engineering with potentially important clinical applications. However, it is still controversial whether Cas13 exhibits collateral activity in mammalian cells. RESULTS: Here, we find that knocking down gene expression using RfxCas13d in the adult brain neurons caused death of mice, which may result from the collateral activity of RfxCas13d rather than the loss of target gene function or off-target effects. Mechanistically, we show that RfxCas13d exhibits collateral activity in mammalian cells, which is positively correlated with the abundance of target RNA. The collateral activity of RfxCas13d could cleave 28s rRNA into two fragments, leading to translation attenuation and activation of the ZAKα-JNK/p38-immediate early gene pathway. CONCLUSIONS: These findings provide new mechanistic insights into the collateral activity of RfxCas13d in mammalian cells and warn that the biosafety of the CRISPR-Cas13 system needs further evaluation before application to clinical treatments. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13059-023-02860-w.